RADNOR, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious diseases, today announced that the Company presented data on its defensin-mimetic antimicrobial compounds at the 52 nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The presentations included results of the first Phase 2 clinical study of PolyMedix's lead defensin-mimetic, brilacidin (PMX-30063), which showed high clinical response rates in patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus.
"We are excited to present data at ICAAC from our first Phase 2 study with brilacidin and our preclinical studies with other defensin-mimetic compounds," said Dr. Richard Scott, Vice President of Research at PolyMedix. "We are proud to be the pioneers in developing defensin-mimetics, a novel class of antibiotics with a distinct mechanism of action from currently known drugs. We look forward to advancing the development of these innovative compounds and exploring their potential to treat a wide range of infectious diseases."
|Study Visit||Low dose n=40||Medium dose n=35||High dose n=39||Daptomycin n=47|
|Data based on per protocol patient population.|